↓ Skip to main content

Pharmacotherapy for Neonatal Seizures: Current Knowledge and Future Perspectives

Overview of attention for article published in Drugs, March 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

twitter
39 X users
facebook
3 Facebook pages

Citations

dimensions_citation
66 Dimensions

Readers on

mendeley
159 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Pharmacotherapy for Neonatal Seizures: Current Knowledge and Future Perspectives
Published in
Drugs, March 2016
DOI 10.1007/s40265-016-0554-7
Pubmed ID
Authors

Maria D. Donovan, Brendan T. Griffin, Liudmila Kharoshankaya, John F. Cryan, Geraldine B. Boylan

Abstract

Seizures are the most common neurological emergencies in the neonatal period and are associated with poor neurodevelopmental outcomes. Seizures affect up to five per 1000 term births and population-based studies suggest that they occur even more frequently in premature infants. Seizures are a sign of an underlying cerebral pathology, the most common of which is hypoxic-ischaemic encephalopathy in term infants. Due to a growing body of evidence that seizures exacerbate cerebral injury, effective diagnosis and treatment of neonatal seizures is of paramount importance to reduce long-term adverse outcomes. Electroencephalography is essential for the diagnosis of seizures in neonates due to their subtle clinical expression, non-specific neurological presentation and a high frequency of electro-clinical uncoupling in the neonatal period. Hypoxic-ischaemic encephalopathy may require neuroprotective therapeutic hypothermia, accompanying sedation with opioids, anticonvulsant drugs or a combination of all of these. The efficacy, safety, tolerability and pharmacokinetics of seven anticonvulsant drugs (phenobarbital, phenytoin, levetiracetam, lidocaine, midazolam, topiramate and bumetanide) are reviewed. This review is focused only on studies reporting electrographically confirmed seizures and highlights the knowledge gaps that exist in optimal treatment regimens for neonatal seizures. Randomised controlled trials are needed to establish a safe and effective treatment protocol for neonatal seizures.

X Demographics

X Demographics

The data shown below were collected from the profiles of 39 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 159 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
New Zealand 1 <1%
Unknown 158 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 20 13%
Student > Master 20 13%
Student > Postgraduate 18 11%
Other 14 9%
Student > Ph. D. Student 14 9%
Other 38 24%
Unknown 35 22%
Readers by discipline Count As %
Medicine and Dentistry 63 40%
Neuroscience 14 9%
Agricultural and Biological Sciences 7 4%
Nursing and Health Professions 7 4%
Pharmacology, Toxicology and Pharmaceutical Science 4 3%
Other 16 10%
Unknown 48 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 24. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 April 2016.
All research outputs
#1,447,406
of 23,848,132 outputs
Outputs from Drugs
#126
of 3,349 outputs
Outputs of similar age
#24,679
of 302,270 outputs
Outputs of similar age from Drugs
#5
of 32 outputs
Altmetric has tracked 23,848,132 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,349 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.4. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 302,270 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.